AnaptysBio Announces Appointment of Rita Jain, M.D., to Board of Directors
07 April 2023 - 6:15AM
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology
company focused on delivering innovative immunology therapeutics,
today announced the appointment of Rita Jain, M.D., to the
company’s Board of Directors, effective immediately. Additionally,
Laura J. Hamill has decided to resign from the company’s Board of
Directors.
“Rita is a recognized leader in rheumatology with
extensive drug development expertise across a wide range of
therapeutic areas across autoimmune and inflammatory diseases that
strongly complements AnaptysBio’s Board experience,”
said Daniel Faga, interim president and chief executive
officer of AnaptysBio. “Importantly, Rita has been
part of multiple biopharma companies at times of rapid growth and
strategic transition. Her insights will be invaluable to us as we
continue to focus our business on advancing immune cell modulators
for people living with autoimmune and inflammatory diseases.”
“I am excited to join AnaptysBio. Their portfolio of
best-in-class immune cell modulating antibodies have the potential
to address significantly underserved patient populations,” said Dr.
Jain. “I look forward to partnering with the AnaptysBio team to
deliver on multiple Phase 2 readouts across two wholly owned
checkpoint agonists targeting PD-1 and BTLA, as well as to advance
ANB033, a CD122 antagonist, through clinical proof-of-concept and
to help guide these programs through late-stage development.”
Dr. Jain is a rheumatologist and currently serves on the Board
of Directors of Provention Bio, Inc. and Celldex Therapeutics, and
serves on the supervisory board of AM Pharma. She previously served
on the Board of Directors of ChemoCentryx, Inc. until its
acquisition by Amgen. Dr. Jain has served as executive vice
president and chief medical officer of ChemoCentryx, Inc., chief
medical officer of Immunovant, Inc. and prior to that, senior vice
president and chief medical officer of Akebia Therapeutics, Inc.
Before joining Akebia, Dr. Jain was vice president of Men's and
Women's Health and Metabolic Development at AbbVie, Inc. and served
in various leadership roles at Abbott Laboratories, including
divisional vice president. Prior to her time at Abbott, she held
management positions in the Arthritis, Inflammation and Pain Group
at G.D. Searle, which was acquired by Pharmacia and, later, Pfizer.
She was responsible for leading the design and execution of
multiple late-stage programs, including for Orilissa® and Oriahnn®
and has also led programs across a diverse set of therapeutic
areas, including immunology, inflammation, pain and nephrology.
Earlier in her career, Dr. Jain served as a faculty member at North
Shore University Hospital in New York.
Dr. Jain received her M.D. from the State University of New York
at Stony Brook School of Medicine and her B.S. in Biology from Long
Island University.
Also, Ms. Hamill has notified the company of her resignation
from the company’s Board of Directors effective April 1, 2023.
Ms. Hamill joined the AnaptysBio Board of Directors in September
2019. Over this almost 4-year period, she significantly contributed
to the strategic direction of the company and provided valuable
business and commercial contributions. The Board of Directors and
the company’s management team would like to thank Ms. Hamill for
her commitment to AnaptysBio and wish her well in her future
endeavors.
About AnaptysBio
AnaptysBio is a clinical-stage biotechnology company focused on
delivering innovative immunology therapeutics. It is developing
immune cell modulators, including two checkpoint agonists in
clinical-stage development, for autoimmune and inflammatory
disease: rosnilimab, its PD-1 agonist, in a planned Phase 2b trial
for the treatment of moderate-to-severe rheumatoid arthritis; and
ANB032, its BTLA agonist, in a planned Phase 2b trial for the
treatment of moderate-to-severe atopic dermatitis. Its preclinical
immune cell modulator portfolio includes ANB033, an anti-CD122
antagonist antibody for the treatment of autoimmune and
inflammatory diseases. In addition, AnaptysBio has developed two
cytokine antagonists available for out-licensing: imsidolimab, an
anti-IL-36R antagonist, in Phase 3 for the treatment of generalized
pustular psoriasis, or GPP, and etokimab, an anti-IL-33 antagonist
for the treatment of respiratory disorders that is Phase 2/3 ready.
AnaptysBio has also discovered multiple therapeutic antibodies
licensed to GSK in a financial collaboration for immune-oncology,
including an anti-PD-1 antagonist antibody (Jemperli
(dostarlimab-gxly)), an anti-TIM-3 antagonist antibody (cobolimab,
GSK4069889) and an anti-LAG-3 antagonist antibody (GSK4074386).
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995, including, but not
limited to: the company’s ability to find a licensing partner for
imsidolimab or etokimab and the timing of any such transaction.
Statements including words such as “plan,” “continue,” “expect,” or
“ongoing” and statements in the future tense are forward-looking
statements. These forward-looking statements involve risks and
uncertainties, as well as assumptions, which, if they do not fully
materialize or prove incorrect, could cause its results to differ
materially from those expressed or implied by such forward-looking
statements. Forward-looking statements are subject to risks and
uncertainties that may cause the company’s actual activities or
results to differ significantly from those expressed in any
forward-looking statement, including risks and uncertainties
related to the company’s ability to advance its product candidates,
obtain regulatory approval of and ultimately commercialize its
product candidates, the timing and results of preclinical and
clinical trials, the company’s ability to fund development
activities and achieve development goals, the company’s ability to
protect intellectual property and other risks and uncertainties
described under the heading “Risk Factors” in documents the company
files from time to time with the Securities and Exchange
Commission. These forward-looking statements speak only as of the
date of this press release, and the company undertakes no
obligation to revise or update any forward-looking statements to
reflect events or circumstances after the date hereof.
Contact:Nick MontemaranoSenior Director,
Investor Relations and Strategic Communications AnaptysBio, Inc.
858.732.0178investors@anaptysbio.com
AnaptysBio (NASDAQ:ANAB)
Historical Stock Chart
From Jun 2024 to Jul 2024
AnaptysBio (NASDAQ:ANAB)
Historical Stock Chart
From Jul 2023 to Jul 2024